logo

Slide Shows

Share
Events

Biotech Stocks Facing FDA Decision In December 2022 Now, let’s take a look at the biotech stocks facing FDA decision in December.

Biotech Stocks Facing FDA Decision In November 2022 The FDA has approved 28 novel drugs so far this year, including 2 in October

Biotech Stocks Facing FDA Decision In October 2022 The FDA has approved only 24 novel drugs this year (Jan. to Sep.) compared to 40 during the same period last year.

Biotech Stocks Facing FDA Decision In September The month of August witnessed the FDA approving the first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions on Aug.17. This one-time gene therapy by the name Zynteglo, developed by bluebird bio Inc. (BLUE), reportedly carries a price tag of $2.8 million.

Biotech Stocks Facing FDA Decision In June 2022 As another month comes to a close, it’s time to take a look back at some of the healthcare sector news that made headlines in May and look ahead to what’s in store on the regulatory front in June.

Biotech Stocks Facing FDA Decision In March 2022 As another month comes to an end, it’s time to take a look back at some of the regulatory news that made headlines in February and look ahead to what the month of March has in store.

Biotech Stocks Facing FDA Decision In February 2022 As we head into February, it's time to take a look back at some of the regulatory news that made headlines in January.

Biotech Stocks Facing FDA Decision In January 2022 As another month comes to an end, we take a look back at some of the regulatory news that dominated the headlines and look ahead to what’s in store for January.